A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Study Summary

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.

Conditions

GIST

Interventions / Drugs

Inlexisertib Ripretinib

View on ClinicalTrials.gov ↗

Sponsor

DCPH

Deciphera Pharmaceuticals

Oncology

D40/100

Study Details

Enrollment94 participants

Primary Completion—

Lead SponsorDeciphera Pharmaceuticals, LLC

Data Retrieved2026-04-11 04:11:28.433199+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.